Related Experiment Videos
The relation between type of renal disease and renal drug clearance in children
1Ohio State University, Columbus.
Insights
The type of renal disease impacts how children eliminate cefotaxime and its metabolite. Intrinsic renal disease preserves tubular secretion, unlike extrinsic renal disease, affecting drug clearance.
Area of Science:
- Pharmacology
- Nephrology
- Pediatrics
Background:
- The intact nephron hypothesis suggests renal drug clearance is uniformly affected by renal impairment.
- Understanding how different renal diseases influence drug pharmacokinetics is crucial for pediatric patients.
Purpose of the Study:
- To investigate the impact of intrinsic versus extrinsic renal disease on cefotaxime and desacetylcefotaxime pharmacokinetics in children.
- To evaluate the intact nephron hypothesis in the context of specific renal pathologies.
Main Methods:
- Two groups of pediatric patients (ages 7-16) with varying renal dysfunction were studied: intrinsic (n=5) and extrinsic (n=5) renal disease.
- Pharmacokinetics were assessed after a single intravenous cefotaxime dose, with blood and urine collected for 24 hours.
- Cefotaxime and desacetylcefotaxime levels were quantified using High-Performance Liquid Chromatography (HPLC).
Main Results:
- No significant differences were observed between groups in age, body surface area, urine output, or overall cefotaxime clearance parameters.
- Statistically significant differences were found in the renal clearance to creatinine clearance (CLR:CLCR) ratios for both cefotaxime and desacetylcefotaxime between the groups.
- Patients with intrinsic renal disease exhibited CLR:CLCR ratios > 1, indicating intact tubular secretion despite reduced glomerular filtration.
Conclusions:
- The type of renal disease significantly influences cefotaxime and desacetylcefotaxime renal clearance in children.
- Intrinsic renal disease appears to maintain tubular secretion function, challenging the uniform application of the intact nephron hypothesis.
- These findings highlight the importance of considering specific renal pathologies when managing drug therapy in pediatric patients with kidney impairment.
Abstract:
It is generally assumed that the renal clearance of drugs in patients with renal impairment are affected to a similar extent regardless of the type of renal disease (intact nephron hypothesis). We have studied the effect of underlying renal disease on the pharmacokinetics of cefotaxime and desacetylcefotaxime in two groups of children (ages 7 to 16 y) with varying degrees of renal dysfunction. Patients in group 1 (n = 5) had intrinsic renal disease and those in group 2 (n = 5) had extrinsic renal disease, as identified by the primary renal lesion. After a single intravenous dose of cefotaxime timed blood and urine samples were collected for 24 h; cefotaxime and desacetylcefotaxime were measured by HPLC. There were no significant differences between the groups in age, body surface area, urine output, creatinine clearance, total body clearance, nonrenal clearance, renal clearance, and volume of distribution at steady state of cefotaxime, and renal clearance of desacetylcefotaxime. However, the renal clearance: creatinine clearance (CLR:CLCR) ratios for both cefotaxime [1.34 in group 1 vs. 0.51 in group 2] and desacetylcefotaxime [1.58 in group 1 vs. 0.75 in group 2] were statistically significant between the two groups. Group 1 patients had an average CLR:CLCR ratio greater than 1 for both the parent compound and the metabolite, suggesting that net tubular secretion was still intact, despite a diminished glomerular filtration rate (CLCR = 24 ml.min-1.73 m-2).(ABSTRACT TRUNCATED AT 250 WORDS)